NRG-GY016: A Phase II Study of MK-3475 (Pembrolizumab) + Epacodastat in Recurrent Clear Cell Carcinoma of the Ovary

Summary

This phase II trial studies how well pembrolizumab and epacadostat work in treating patients with ovarian clear cell carcinoma that has come back, remains despite treatment, or is growing, spreading, or getting worse. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and epacadostat may work better in treating patients with ovarian clear cell carcinoma.

More information

Contact us

To learn more about clinical trials at ProHealth Care, email research.institute@phci.org or call 262-928-3447.

Quick Access Links